Michael P. Harrington has been named Executive Vice President and Chief Financial Officer (CFO) at Memorial Sloan Kettering Cancer Center (MSK). Mr. Harrington currently serves as the Associate Chief Financial Officer at the Cleveland Clinic. His appointment concludes a national search to identify a successor for MSK’s current CFO, Michael Gutnick, who will retire after 42 years of exemplary service to MSK.
Memorial Sloan Kettering Cancer Center (MSK) announced its recommitment to communities across Long Island today with the dedication of MSK Nassau, a light-filled 114,000-square-foot outpatient cancer treatment facility centrally located along Hempstead Turnpike. MSK’s newest location, and its third on Long Island, will open for patient care on April 8 with more than 180 dedicated medical and professional staff, all of whom are MSK employees.
The Starr Foundation is continuing its longstanding commitment to stem cell research in New York City with a $50 million gift in support of the Tri-Institutional Stem Cell Initiative (Tri-SCI), a research collaboration between Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine.
LOXO-195, a next-generation TRK inhibitor also known as BAY 2731954, has shown signs of clinical activity in individuals with NTRK gene fusion-positive solid tumors that have become resistant to first-generation TRK inhibitors. Results from a phase I clinical trial and a US Food and Drug Administration expanded access program were presented by David Hyman, MD, the Chief of the Early Drug Development Service at Memorial Sloan Kettering Cancer Center (MSK), at the American Association for Cancer Research (AACR) Annual Meeting 2019. This research is featured in the meeting’s press program, and findings are being presented in the “Next Generation of Clinical Trials in Molecularly Driven Therapy” minisymposium.
— Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest cavity — namely malignant pleural mesothelioma but also metastatic lung and breast cancer. The results from a phase I clinical trial were presented as part of the press program at the American Association for Cancer Research (AACR) Annual Meeting 2019. The findings showed tumor reduction in patients who participated in the study and no evidence of toxicity.
Researchers at Memorial Sloan Kettering Cancer Center (MSK) reported results from a new study that looks at the likelihood of complications for people undergoing bone marrow transplants (BMTs). The observational study found that people with lower gut microbiota diversity before having a transplant appear to be at higher risk for developing complications. These findings further support evidence that the connection between microbiota and outcomes starts before people begin the transplantation process. These findings were presented as part of the 2018 annual meeting of the American Society of Hematology (ASH) press program.
Memorial Sloan Kettering Cancer Center has announced that Oren Cahlon, MD, a renowned radiation oncologist and expert in proton therapy, will assume the position of Associate Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network. With this appointment, which is effective immediately, Dr. Cahlon will help oversee the network’s outpatient clinical programs, which span seven locations across New York and New Jersey.
Memorial Sloan Kettering Cancer Center (MSK) researchers presented the results of a randomized phase III trial at today’s press program for the European Society for Medical Oncology’s 2018 Congress in Munich, Germany. The results demonstrated that a combination of the immune checkpoint blocker avelumab (Bavencio®) and the tyrosine kinase inhibitor (TKI) axitinib (Inlyta®) can significantly improve progression-free survival (PFS) in people who have been previously untreated for advanced renal cell carcinoma (RCC).
Whole breast radiation (WBRT) significantly reduced local recurrence in women with “good risk” (low risk) ductal carcinoma in situ (DCIS) following breast conservation surgery, according to researchers from Memorial Sloan Kettering Cancer Center, who presented this data in a press conference at the annual meeting of the American Society for Radiation Oncology (ASTRO).
The National Academy of Medicine (NAM) has named Hedvig Hricak, MD, PhD, Chair of the Department of Radiology, a recipient of the David Rall Medal. The medal is given annually to a NAM member who has demonstrated outstanding leadership. Dr. Hricak received the award at the 2018 NAM Annual Meeting on Monday, October 15, 2018, in Washington, D.C.